These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15081101)

  • 1. Role of epoetin alfa in maintaining ribavirin dose.
    Afdhal NH
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S25-35. PubMed ID: 15081101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
    Afdhal NH; Dieterich DT; Pockros PJ; Schiff ER; Shiffman ML; Sulkowski MS; Wright T; Younossi Z; Goon BL; Tang KL; Bowers PJ;
    Gastroenterology; 2004 May; 126(5):1302-11. PubMed ID: 15131791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
    Collantes RS; Younossi ZM
    J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S9-13. PubMed ID: 15597026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
    Ong JP; Younossi ZM
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S17-21. PubMed ID: 15468613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
    Bräu N
    J Viral Hepat; 2004 May; 11(3):191-7. PubMed ID: 15117320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
    Talal AH; Liu RC; Zeremski M; Dimova R; Dove L; Pearce D; Hassanein T; Doonquah L; Aboulafia D; Rodriguez J; Bonilla H; Galpin J; Aberg JA; Johnston B; Glesby MJ; Jacobson IM
    J Acquir Immune Defic Syndr; 2011 Nov; 58(3):261-8. PubMed ID: 21876446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to combination therapy: influence on sustained virologic response and economic impact.
    Manns MP
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S11-24. PubMed ID: 15081100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia in the treatment of hepatitis C virus infection.
    Sulkowski MS
    Clin Infect Dis; 2003; 37 Suppl 4():S315-22. PubMed ID: 14582000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
    Mac Nicholas R; Norris S
    Aliment Pharmacol Ther; 2010 May; 31(9):929-37. PubMed ID: 20175767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C.
    Dar Santos AE; Partovi N; Ford JA; Yoshida EM
    Ann Pharmacother; 2007 Feb; 41(2):268-75. PubMed ID: 17299014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
    Dieterich DT; Wasserman R; Bräu N; Hassanein TI; Bini EJ; Bowers PJ; Sulkowski MS
    Am J Gastroenterol; 2003 Nov; 98(11):2491-9. PubMed ID: 14638354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.
    Rivkin AM; Chawla S
    Pharmacotherapy; 2005 Jun; 25(6):862-75. PubMed ID: 15927905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C.
    Sharvadze L; Tsertsvadze T; Gochitashvili N; Kakabadze T; Dolmazashvili E
    Georgian Med News; 2006 Aug; (137):62-5. PubMed ID: 16980747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin.
    Sherman M; Cohen L; Cooper MA; Elkashab M; Feinman V; Fletcher D; Girgrah N; Heathcote J; Levstik M; McNaull WB; Wong D; Wong F; Yim C
    Can J Gastroenterol; 2006 Jul; 20(7):479-85. PubMed ID: 16858501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
    Pockros PJ; Shiffman ML; Schiff ER; Sulkowski MS; Younossi Z; Dieterich DT; Wright TL; Mody SH; Tang KL; Goon BL; Bowers PJ; Leitz G; Afdhal NH;
    Hepatology; 2004 Dec; 40(6):1450-8. PubMed ID: 15565613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
    Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
    Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
    Jacobson IM; Brown RS; Freilich B; Afdhal N; Kwo PY; Santoro J; Becker S; Wakil AE; Pound D; Godofsky E; Strauss R; Bernstein D; Flamm S; Pauly MP; Mukhopadhyay P; Griffel LH; Brass CA;
    Hepatology; 2007 Oct; 46(4):971-81. PubMed ID: 17894303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
    Alvarez D; Dieterich DT; Brau N; Moorehead L; Ball L; Sulkowski MS
    J Viral Hepat; 2006 Oct; 13(10):683-9. PubMed ID: 16970600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.
    Del Rio RA; Post AB; Singer ME
    Hepatology; 2006 Dec; 44(6):1598-606. PubMed ID: 17133490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
    Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.